In addition to the further increase in the ratio of 2-HG/tCho, we found a significantly higher metabolite ratio of myo-Inositol/tCho in IDH2 gliomas (four patients with IDH2 R172K and one patient with IDH2 R172W mutations) compared to IDH1 gliomas (fifteen patients with IDH1 R132H mutation). The gene discussed is IDH2; the disease is central nervous system cancer.